Have a feature idea you'd love to see implemented?
Let us know!
COGT Cogent Biosciences Inc
Price (delayed)
$8.98
Market cap
$991.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.48
Enterprise value
$912.73M
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed
Highlights
The company's debt fell by 7% YoY
The company's equity fell by 16% QoQ but it rose by 3.9% YoY
The company's net income fell by 36% YoY and by 7% QoQ
Cogent Biosciences's quick ratio has decreased by 30% from the previous quarter and by 21% YoY
Key stats
What are the main financial stats of COGT
Market
Valuations
Earnings
Shares outstanding
110.46M
Market cap
$991.95M
Enterprise value
$912.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$242.3M
EBITDA
-$238.26M
Free cash flow
-$192.1M
Per share
Balance sheet
Liquidity
EPS
-$2.48
Free cash flow per share
-$1.74
Book value per share
$2.87
Revenue per share
$0
TBVPS
$3.49
Total assets
$384.02M
Total liabilities
$69.36M
Debt
$17.83M
Equity
$314.66M
Working capital
$288.48M
Debt to equity
0.06
Current ratio
6.44
Quick ratio
6.32
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-60.4%
Return on equity
-70.8%
Return on invested capital
-91.9%
Return on capital employed
-73.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COGT stock price
How has the Cogent Biosciences stock price performed over time
Intraday
-1.1%
1 week
-6.94%
1 month
-24.28%
1 year
30.52%
YTD
52.72%
QTD
-16.85%
Financial performance
How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$260.43M
Net income
-$242.3M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 36% YoY and by 7% QoQ
COGT's operating income is down by 34% year-on-year and by 6% since the previous quarter
Growth
What is Cogent Biosciences's growth rate over time
Valuation
What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
3.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 6% YoY
The P/B is 64% above the 5-year quarterly average of 1.9 and 30% above the last 4 quarters average of 2.4
The company's equity fell by 16% QoQ but it rose by 3.9% YoY
Efficiency
How efficient is Cogent Biosciences business performance
The company's return on equity fell by 13% YoY and by 6% QoQ
COGT's return on invested capital is up by 12% year-on-year but it is down by 7% since the previous quarter
The ROA has contracted by 11% YoY and by 4.7% from the previous quarter
Dividends
What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COGT.
Financial health
How did Cogent Biosciences financials performed over time
The total liabilities rose by 32% year-on-year and by 22% since the previous quarter
Cogent Biosciences's quick ratio has decreased by 30% from the previous quarter and by 21% YoY
The company's debt is 94% lower than its equity
Cogent Biosciences's debt to equity has increased by 20% QoQ
The company's equity fell by 16% QoQ but it rose by 3.9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.